Dr. Amel Menotti  
Bristol Laboratories  
P.O. Box 657  
Syracuse, New York 13201

Dear Amel,

The enclosed paper in Nature from Merck just came to my attention and was particularly interesting because it reminded me of some studies that I had suggested at Bristol many years ago. As you may note from the enclosed reprint at page 153 the sulfonic analogue of DAP that was synthesized, I believe by Lee Cheney, was inactive in vitro under the conditions tested and that effort was dropped.

Now in the light of the Merck report I would like to suggest to you that it might be worth retesting this compound -- if you still have samples -- in vivo.

As I believe we discussed long ago, the half-sulfonic analogue of DAP might be a more plausible candidate as an inhibitory analogue but I do not believe this was pursued.

As you know, I am now connected with Cetus Laboratories as a way of furthering some continuing ideas about antibiotic development. But, of course, this in no way interferes with my hope that there might be some last ditch chance of your exploiting this ancient history.

With best wishes,

Sincerely yours,

Joshua Lederberg  
Professor of Genetics

Enclosure

JL/rr